Abstract
Neuropsychiatric symptoms in human immunodeficiency virus (HIV)-infected patients may be a late complication of efavirenz treatment. This study: 1) assessed the level of neuropsychiatric symptoms in HIV-infected patients on long-term efavirenz therapy; 2) explored the effect of a switch to non-efavirenz containing anti-retroviral treatment on neuropsychiatric symptoms. A consecutive series of 47 HIV-infected participants on long-term efavirenz treatment were included in an observational clinical trial. Participants completed three self-report questionnaires on neuropsychiatric symptoms. Patients switching to a non-efavirenz regimen were retested 2 weeks and 3 months after switching. Data were analyzed using repeated measures ANOVA to assess the effect of switching over time. A change in the percentage of patients scoring above norm scores after switching was analyzed using Chi square. Neuropsychiatric symptoms were common among HIV-infected patients on long-term efavirenz therapy, mainly depression, anxiety, stress, insufficiency in thinking and paranoia. After switching, these symptoms improved significantly to (near) normal levels. Our results show that neuropsychiatric symptoms are common among HIV-infected subjects and may be caused by long-term efavirenz use. Neuropsychiatric assessment, such as the Depression, Anxiety and Stress scale and Symptom Checklist 90, can identify those that may benefit from the discontinuation of efavirenz.
Keywords: Efavirenz, efavirenz discontinuation, long-term efavirenz, neuropsychiatric assessment, self-report questionnaires.
CNS & Neurological Disorders - Drug Targets
Title:Improvement of Depression and Anxiety After Discontinuation of Long- Term Efavirenz Treatment
Volume: 14 Issue: 6
Author(s): Khutso M. Mothapo, Arnt Schellekens, Reinout van Crevel, Monique Keuter, K. Grintjes-Huisman, Peter Koopmans and Andre van der Ven
Affiliation:
Keywords: Efavirenz, efavirenz discontinuation, long-term efavirenz, neuropsychiatric assessment, self-report questionnaires.
Abstract: Neuropsychiatric symptoms in human immunodeficiency virus (HIV)-infected patients may be a late complication of efavirenz treatment. This study: 1) assessed the level of neuropsychiatric symptoms in HIV-infected patients on long-term efavirenz therapy; 2) explored the effect of a switch to non-efavirenz containing anti-retroviral treatment on neuropsychiatric symptoms. A consecutive series of 47 HIV-infected participants on long-term efavirenz treatment were included in an observational clinical trial. Participants completed three self-report questionnaires on neuropsychiatric symptoms. Patients switching to a non-efavirenz regimen were retested 2 weeks and 3 months after switching. Data were analyzed using repeated measures ANOVA to assess the effect of switching over time. A change in the percentage of patients scoring above norm scores after switching was analyzed using Chi square. Neuropsychiatric symptoms were common among HIV-infected patients on long-term efavirenz therapy, mainly depression, anxiety, stress, insufficiency in thinking and paranoia. After switching, these symptoms improved significantly to (near) normal levels. Our results show that neuropsychiatric symptoms are common among HIV-infected subjects and may be caused by long-term efavirenz use. Neuropsychiatric assessment, such as the Depression, Anxiety and Stress scale and Symptom Checklist 90, can identify those that may benefit from the discontinuation of efavirenz.
Export Options
About this article
Cite this article as:
Mothapo M. Khutso, Schellekens Arnt, Crevel van Reinout, Keuter Monique, Grintjes-Huisman K., Koopmans Peter and der Ven van Andre, Improvement of Depression and Anxiety After Discontinuation of Long- Term Efavirenz Treatment, CNS & Neurological Disorders - Drug Targets 2015; 14 (6) . https://dx.doi.org/10.2174/1871527314666150325235847
DOI https://dx.doi.org/10.2174/1871527314666150325235847 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Design of Iodine-Lithium-α-Dextrin Liquid Crystal with Potent Antimicrobial and Anti-Inflammatory Properties
Current Pharmaceutical Design NPFF2 Receptor is Involved in the Modulatory Effects of Neuropeptide FF for Macrophage Cell Line
Protein & Peptide Letters Apoptosis: A Key in Neurodegenerative Disorders
Current Neurovascular Research Selective Modulator of Cannabinoid Receptor Type 2 Reduces Memory Impairment and Infarct Size During Cerebral Hypoperfusion and Vascular Dementia
Current Neurovascular Research Convolution Neural Network Based Visual Speech Recognition System for Syllable Identification
Recent Advances in Computer Science and Communications Neurotrophic and Neuroprotective Effects of Muscle Contraction
Current Pharmaceutical Design Teratological Consequences of Nitric Oxide Synthesis Inhibition
Current Pharmaceutical Design Role of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) in Different Disease States: Recent Updates
Current Medicinal Chemistry Pathogenesis, Experimental Models and Contemporary Pharmacotherapy of Irritable Bowel Syndrome: Story About the Brain-Gut Axis
Current Neuropharmacology The Updated Role of Oxidative Stress in Subarachnoid Hemorrhage
Current Drug Delivery Microglia Phenotype Diversity
CNS & Neurological Disorders - Drug Targets LFA-1 as a Key Regulator of Immune Function: Approaches toward the Development of LFA-1-Based Therapeutics
Current Pharmaceutical Design Functional Roles of Synaptic and Extrasynaptic NMDA Receptors in Physiological and Pathological Neuronal Activities
Current Drug Targets Recent Advances on Horizontal Lower Limb Rehabilitation Robot
Recent Patents on Mechanical Engineering Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued) Levosimendan Reduces Prostaglandin F2a-dependent Vasoconstriction in Physiological Vessels and After Experimentally Induced Subarachnoid Hemorrhage
Current Neurovascular Research The Multi-faceted Profile of Corticotropin-releasing Factor (CRF) Family of Neuropeptides and of their Receptors on the Paracrine/Local Regulation of the Inflammatory Response
Current Molecular Pharmacology Gene Therapy as a Novel Pharmaceutical Intervention for Stroke
Current Pharmaceutical Design Large A-V Fistula: Pathophysiological Consequences and Therapeutic Perspectives
Current Vascular Pharmacology Davunetide: Peptide Therapeutic in Neurological Disorders
Current Medicinal Chemistry